The group's principal activity is to develop drugs for HIV and multiple sclerosis. The group is a biotechnology holding company that owns non-exclusive license rights to patents and intellectual property related to the development of drugs. These technologies are being developed by receptopharm, inc. The group's subsidiary infectech, inc is engaged in the research and development of diagnostic test kits designed to be used for the rapid identification of infectious human diseases such as tuberculosis (tb) and mycobacterium avium-intracellulare (mai). On 19-Sep-2003, the group acquired infectech inc.
